Adrián Mosquera Orgueira, MD, PhD,

Adrián Mosquera Orgueira, MD, PhD, is a specialist in Hematology and Hemotherapy and lead researcher of the Computational and Genomic Hematology Group at the Health Research Institute of Santiago de Compostela.

Articles by Adrián Mosquera Orgueira, MD, PhD,

Dr Mosquera Orgueira on the Development of a Machine Learning–Based Prognostic Model for Risk Stratification in Myelofibrosis

ByAdrián Mosquera Orgueira, MD, PhD,

May 29th 2025

Dr Orgueira on Refining the Use of Machine Learning to Predict Survival Outcomes After Transplant in Myelofibrosis

ByAdrián Mosquera Orgueira, MD, PhD,

May 19th 2025

Adrián Mosquera Orgueira, MD, PhD, discusses research to improve machine learning models for predicting post-transplant survival outcomes in myelofibrosis.

Dr Orgueira on the Use of Machine Learning to Predict Survival Outcomes After Allo-HSCT in Myelofibrosis

ByAdrián Mosquera Orgueira, MD, PhD,

April 15th 2025

Adrián Mosquera Orgueira, MD, PhD, discusses whether machine learning could accurately predict OS and NRM outcomes after allo-HSCT in myelofibrosis.

Adrián Mosquera Orgueira, MD, PhD,

Articles by Adrián Mosquera Orgueira, MD, PhD,

Dr Mosquera Orgueira on the Development of a Machine Learning–Based Prognostic Model for Risk Stratification in Myelofibrosis

Dr Orgueira on Refining the Use of Machine Learning to Predict Survival Outcomes After Transplant in Myelofibrosis

Dr Orgueira on the Use of Machine Learning to Predict Survival Outcomes After Allo-HSCT in Myelofibrosis

Latest Updated Articles

Trending on OncLive

FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC

Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM

FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma

FDA Approval Tees Up T-DXd Plus Pertuzumab as a New SOC in HER2+ Breast Cancer

NALIRIFOX and FOLFIRINOX Facilitate Personalized Treatment in Metastatic Pancreatic Cancer